Project Grant R01HL178539
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $512,815 Project Grant from the National Heart, Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 5, 2025, with completion targeted for May 31, 2029. The research investigates mechanistic diversity in biased angiotensin II type 1 receptor (AT1R) ligands, which are compounds that preferentially activate specific cellular signaling...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $160,040 Project Grant from the National Heart, Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 30, 2025, with completion targeted for September 4, 2027. The project investigates the development and efficacy of Partially Ordered Polypeptides (POPs)—an injectable biomaterial scaffold—to improve patient outcomes following myocardial...
- Federal Project Grant Award Summary Duke University received a $1.48 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 15, 2025, with completion targeted for June 30, 2029. The award supports the development of an improved Intensive Care Unit (ICU) mortality risk prediction model designed to address documented measurement errors in widely used prognostic tools such as Acute...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $242,250 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 1, 2025 through June 30, 2027. This award funds research examining the relationship between atrial fibrillation (AF), oral anticoagulation therapy, and retinal stroke (central retinal artery occlusion) using an instrumental variable...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $242,250 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion targeted for August 31, 2027. This feasibility study (R03 mechanism) implements arteriovenous blood sampling techniques to measure regional metabolic changes in the heart and legs during submaximal exercise...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $251,966 Project Grant from the National Heart, Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 1, 2025, with completion expected May 31, 2027. This K99/R00 award supports fundamental research to identify novel molecular regulators of cardiomyocyte polyploidy—the process by which heart muscle cells undergo whole genome duplication...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $165,456 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 15, 2025, with completion scheduled for June 30, 2030. This award supports fundamental research investigating the role of protein S-palmitoylation in transforming growth factor beta (TGF-β) signaling and its contribution to...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $798,698 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 10, 2025, with completion targeted for June 30, 2030. The project, titled "Cardiac Function and Proteomic Biomarkers in Individuals with Perinatal HIV Infection or Exposure," aims to comprehensively characterize cardiac dysfunction...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $107,752 Project Grant awarded September 12, 2025, by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports a research initiative titled "Epithelial Cell Mediated Fibroblast Activation Through CTHRC1-TGFB Signaling in Fibrotic Lung Diseases," with a completion date of August 31, 2027. The research...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $776,129 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025 through June 30, 2029. The award funds research to detect growth of intracranial aneurysms using non-invasive photon counting CT (PCCT) imaging in murine models. The project will establish optimized PCCT protocols for high-resolution...
Duke University's Office of Research Administration received a $1,532,545 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective June 5, 2026, with completion targeted for February 29, 2028. The research project investigates the effects of income-based health insurance benefit designs on cardiovascular disease (CVD) outcomes and health disparities among working-age adults. Specifically, the study will analyze whether employers' targeted provision of more generous health benefits—such as lower deductibles or free cardioprotective medications—to low-income workers (while offering high-deductible health plans to higher-income employees) improves CVD care quality, patient outcomes, and overall healthcare spending efficiency. The research leverages a large national health insurance claims database covering approximately 10 million working-age individuals from 2012 through 2027 to evaluate this novel approach to reducing cost-related barriers to care in the private U.S. health system. This project directly addresses the NHLBI's mission to promote prevention and treatment of cardiovascular disease through evidence-based research, with particular relevance to reducing health disparities affecting low-income populations who experience disproportionate CVD burden. The findings will provide critical evidence on the feasibility and effectiveness of population-tailored benefit designs as a policy mechanism within employer-sponsored health insurance.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.5m | 6/8/26 |